Acura Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 04:21 pm
Share
Acura Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 0.27 million compared to USD 0.41 million a year ago. Net loss was USD 0.262 million compared to USD 0.678 million a year ago.
For the nine months, revenue was USD 1.53 million compared to USD 2.85 million a year ago. Net loss was USD 0.908 million compared to USD 0.965 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.03 a year ago.
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.